DLA
AUPH icon

Douglas Lane & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

Douglas Lane & Associates’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,200
Closed -$52.7K – 229
2022
Q4 		$52.7K Buy
+12,200
New +$70.8K ﹤0.01% 224

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Douglas Lane & Associates's AUPH Position: Q1 2023 in Review

Douglas Lane & Associates sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2023, closing a stake of 12,200 shares — an estimated $52.7K sold.

Douglas Lane & Associates first reported a position in AUPH in Q4 2022 and held it in 1 quarter. The position peaked at $52.7K in Q4 2022. 186 funds tracked by Wall St. Rank hold AUPH as of Q1 2023.

  • Douglas Lane & Associates reported no remaining Aurinia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Douglas Lane & Associates sold 12,200 Aurinia Pharmaceuticals shares in Q1 2023, an estimated $52.7K.
  • Douglas Lane & Associates first reported a position in Aurinia Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Douglas Lane & Associates's Aurinia Pharmaceuticals position peaked at $52.7K in Q4 2022.
  • 186 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2023.

Based on Douglas Lane & Associates's 13F filing for Q1 2023, filed 17 Apr 2023.